The Neuroscience of Being Human

The Neuroscience of Ayahuasca and DMT

How a tryptamine hallucinogen that the brain may produce endogenously creates the most intense altered state known to pharmacology, why ayahuasca requires a monoamine oxidase inhibitor to work orally, and what clinical trials reveal about antidepressant potential

1,560-word article with 8 Harvard references.

The pharmacology of DMT

N,N-dimethyltryptamine is structurally simple. It is tryptamine, the backbone of serotonin, with two methyl groups attached to the terminal nitrogen. This minor structural modification transforms an inactive precursor into one of the most potent hallucinogens known. Strassman et al. (1994), conducting the first new human DMT research in the United States in more than twenty years, administered intravenous DMT to experienced hallucinogen users at four dose levels. The dose-response relationship was orderly and steep. At the lowest dose, participants reported mild perceptual changes. At the highest dose, participants reported complete dissolution of the ordinary visual field, replacement by elaborate geometric patterns and complex scenes, encounters with apparently autonomous entities, and a conviction that they had entered an alternative dimension of reality. The onset was immediate. The peak occurred within two minutes. The entire experience resolved within fifteen to twenty minutes. No other hallucinogen acts with this speed or intensity.

The primary pharmacological mechanism is agonism at the 5-HT2A serotonin receptor, the same receptor targeted by psilocybin and LSD. However, DMT also has significant affinity for sigma-1 receptors, a class of intracellular chaperone proteins involved in cellular stress responses, neuroprotection, and immune modulation. Frecska et al. (2013) proposed that DMT's sigma-1 receptor activity may serve an endogenous protective function, potentially mobilised during extreme physiological stress such as cardiac arrest or severe hypoxia. This hypothesis remains speculative but has generated considerable research interest, particularly given the detection of endogenous DMT synthesis in the mammalian brain.

Endogenous DMT: a hallucinogen the brain makes itself

The idea that the human brain produces its own supply of a powerful hallucinogen has fascinated researchers since DMT was first identified in human blood and urine in the 1960s. The question was whether these trace amounts were physiologically meaningful or merely metabolic noise. Dean et al. (2019) provided the most significant advance in this question by demonstrating, using in vivo microdialysis in living rat brains, that DMT is present in the extracellular space of the cerebral cortex at concentrations comparable to other monoamine neurotransmitters including serotonin and dopamine. They further demonstrated that the enzyme responsible for DMT synthesis, indolethylamine-N-methyltransferase, is expressed in cortical neurons, pineal gland, and choroid plexus. DMT is not a metabolic accident. It is actively synthesised by identified neurons in specific brain regions.

The function of endogenous DMT remains unknown. Hypotheses include a role in dreaming, a role in the neurochemistry of dying, a role in immune modulation via sigma-1 receptors, and a role in neural plasticity. What is established is that the mammalian brain possesses the enzymatic machinery to synthesise DMT, that it does synthesise it, and that it is present in the extracellular fluid of the cortex at concentrations that could plausibly activate receptors. The brain has, for reasons that neuroscience has not yet determined, retained the capacity to produce a molecule that, when administered exogenously, generates the most intense altered state of consciousness in the pharmacological repertoire.

Ayahuasca: the pharmacological problem of oral DMT

DMT is orally inactive. Monoamine oxidase A, an enzyme abundantly expressed in the gut wall and liver, degrades DMT before it can reach the systemic circulation. If you swallow pure DMT, nothing happens. The indigenous peoples of the Amazon basin solved this pharmacological problem centuries before Western science understood it. McKenna et al. (1984) documented the chemistry: ayahuasca combines DMT-containing plants, typically Psychotria viridis or Diplopterys cabrerana, with the vine Banisteriopsis caapi, which contains the beta-carboline alkaloids harmine, harmaline, and tetrahydroharmine. These beta-carbolines are potent, reversible inhibitors of monoamine oxidase A. By inhibiting the enzyme that would otherwise destroy DMT during first-pass metabolism, they allow orally consumed DMT to reach the bloodstream, cross the blood-brain barrier, and activate central 5-HT2A receptors.

Riba et al. (2003) conducted the first controlled human pharmacological study of ayahuasca, administering the preparation to experienced users under clinical conditions. They documented the pharmacokinetic profile: DMT plasma concentrations peaked at approximately ninety minutes, subjective effects peaked at approximately two hours, and the total duration was approximately four hours. The experience was qualitatively similar to intravenous DMT, intense visual hallucinations, altered perception of time and space, emotional amplification, but temporally extended. The gradual onset and longer duration allowed psychological processing that the fifteen-minute intravenous experience does not permit, a feature that may be therapeutically relevant.

Antidepressant effects: the clinical evidence

Palhano-Fontes et al. (2019) published the first randomised, double-blind, placebo-controlled trial of ayahuasca for treatment-resistant depression. Twenty-nine patients who had failed to respond to at least two adequate trials of conventional antidepressants received either a single dose of ayahuasca or placebo. Depression scores were measured at one, two, and seven days post-treatment. The ayahuasca group showed significant reductions in depression severity at all time points. At day seven, the response rate in the ayahuasca group was sixty-four percent compared to twenty-seven percent in the placebo group. The effect sizes were large. The results were consistent with earlier open-label studies and with the broader psychedelic therapy literature for psilocybin and LSD.

dos Santos et al. (2016), conducting a systematic review of clinical trials of ayahuasca, psilocybin, and LSD, found that all three serotonergic psychedelics demonstrated anxiolytic and antidepressant effects in the studies reviewed. The mechanisms likely involve 5-HT2A receptor-mediated increases in neural plasticity, enhanced functional connectivity between brain regions that are typically segregated, and the psychological processing facilitated by the altered state itself. Ayahuasca may have additional pharmacological advantages: the beta-carboline alkaloids in the preparation have independent antidepressant properties through MAO inhibition and may contribute to the therapeutic effect beyond their role in enabling oral DMT absorption.

The near-death experience overlap

Timmermann et al. (2018) administered intravenous DMT to thirteen healthy volunteers and compared their experience reports with validated measures of near-death experiences. The overlap was striking. DMT experiences scored significantly on near-death experience scales, with strong loadings on factors including entering an unearthly realm, encountering a mystical being or presence, feelings of peace and joy, a sense of cosmic unity, and the conviction that the experience was more real than ordinary consciousness. The correlation raises the question of whether endogenous DMT release might contribute to the phenomenology of actual near-death experiences, a hypothesis that remains unproven but is consistent with the demonstrated presence of DMT synthesis machinery in the brain and with the observation that cardiac arrest, the most common context for near-death experiences, involves precisely the kind of extreme physiological stress that Frecska et al. (2013) hypothesised might trigger endogenous DMT release via sigma-1 receptor pathways.